Checkpoint Therapeutics Price to Book Ratio 2016-2021 | CKPT

Historical price to book ratio values for Checkpoint Therapeutics (CKPT) over the last 10 years. The current price to book ratio for Checkpoint Therapeutics as of October 15, 2021 is 4.83.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Checkpoint Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-15 3.32 4.83
2021-06-30 2.95 $0.69 4.29
2021-03-31 3.14 $0.68 4.59
2020-12-31 2.65 $0.51 5.20
2020-09-30 2.68 $0.53 5.02
2020-06-30 1.98 $0.26 7.67
2020-03-31 1.51 $0.29 5.12
2019-12-31 1.72 $0.35 4.93
2019-09-30 2.49 $0.16 15.16
2019-06-30 3.03 $0.20 15.54
2019-03-31 2.86 $0.20 14.50
2018-12-31 1.82 $0.35 5.25
2018-09-30 3.58 $0.65 5.52
2018-06-30 2.98 $0.69 4.29
2018-03-31 4.39 $0.90 4.86
2017-12-31 3.88 $0.59 6.58
2017-09-30 8.20 $0.78 10.50
2017-06-30 9.95 $0.98 10.12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.275B $0.001B
Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00